Cite
Hewitt DB, Nissen N, Hatoum H, et al. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. Ann Surg. 2020;doi: 10.1097/SLA.0000000000004669.
Hewitt, D. B., Nissen, N., Hatoum, H., Musher, B., Seng, J., Coveler, A. L., Al-Rajabi, R., Yeo, C. J., Leiby, B., Banks, J., Balducci, L., Vaccaro, G., LoConte, N., George, T. J., Brenner, W., Elquza, E., Vahanian, N., Rossi, G., Kennedy, E., Link, C., & Lavu, H. (2020). A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. Annals of surgery, . https://doi.org/10.1097/SLA.0000000000004669
Hewitt, D Brock, et al. "A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer." Annals of surgery vol. (2020). doi: https://doi.org/10.1097/SLA.0000000000004669
Hewitt DB, Nissen N, Hatoum H, Musher B, Seng J, Coveler AL, Al-Rajabi R, Yeo CJ, Leiby B, Banks J, Balducci L, Vaccaro G, LoConte N, George TJ, Brenner W, Elquza E, Vahanian N, Rossi G, Kennedy E, Link C, Lavu H. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. Ann Surg. 2020 Dec 22; doi: 10.1097/SLA.0000000000004669. Epub 2020 Dec 22. PMID: 33630475.
Copy
Download .nbib